Online: 20-22 October 2021 | from your office or home
Overview
Neutralizing antibodies (NAbs) are critical human immune defense mechanisms against viral infections. NAbs can bind to sites on the virus and inhibit entry of that virus into the host.
In this webinar, we have invited Dr. Yanfeng Li from GenScript Biotech Corporation to discuss about challenges in COVID-19 management; post vaccination NAb evaluation & protection versus new variants; and limitations of existing serology methods.
We will also review cPassTM clinical performance, NAb longevity in infected & vaccinated individuals, and why cPassTM can potentially serve as COVID-19 ‘exit strategy’ to reopen the economy and society.
About GenScript Biotech Corporation: global leading biotech company with gene synthesis, protein, antibody and preclinical drug development service capabilities.
About cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit: cPass™ kit allows rapid detection of total neutralizing antibodies (NAbs) in a sample. NAbs are functional antibodies that specifically block the interaction between virus and host cell and therefore prevent the viral entry into the host cell. The cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit was co-developed by Duke-NUS Medical School (Duke-NUS), GenScript, and DxD Hub.
Learning objectives
- To discuss the current challenges in COVID-19 management
- To understand the post-vaccination Neutralization Antibodies evaluation and protection versus new variants
- To overcome the limitations of existing serology methods
Speakers
Tay Boon Hwa
Regional Marketing Specialist, GenScript Biotech Corporation
Tay Boon Hwa is the Regional Marketing Specialist at GenScript Asia Pacific. He is passionate about developing high quality online and offline conferences, as well as implementing marketing plans in South East Asia, Middle East and Australasia. He handled more than 10 webinars and virtual conferences, and 2 regional promotions in the past 6 months. With the background of Biotechnology, he is capable of incorporating latest life science technology of GenScript Biotech into the marketing campaign and promotional activities.
Yanfeng Li
Head of IVD Business, GenScript Biotech Corporation
Yanfeng Li, Ph.D. is the Head of IVD Business, APAC at GenScript. She is well trained in Cellular Biology & Immunology, with extensive research experience in signalling pathways determining B cell biology and T cell functionality. She authored in more than 10 world renowned journals and led over 50 successful clinical trials connecting insights from consumer behaviour, skin biology and intervention efficacy. Yanfeng is passionate about the surrogate virus neutralizing test technology and an advocate to promote ‘exit strategy’ from COVID-19 using cPass™ Test.
.png){kind=logo}
